VERV Live signals | Maximize Profits with Getagraph.com

SELL 157750 min ago

@ $12.71

Issued: 14 Feb 2024 @ 14:22

Return: -59.17%

Previous signal: Feb 14 - 12:04

Previous signal: Buy

Return: 0.87 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	1.54M
Average Volume	1.40M
Market Cap	407.67M
EPS	$0 ( 2024-05-20 )
Next earnings date	( $-0.680 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.810
ATR14	$0.00800 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-14	Ashe Andrew D.	Buy	76 000	Common Stock
2024-04-01	Nickerson Joan	Buy	3 315	Common Stock
2024-04-01	Nickerson Joan	Sell	3 315	Restricted Stock Units
2024-04-02	Nickerson Joan	Sell	1 514	Common Stock
2024-02-14	Ashe Andrew D.	Buy	150 000	Stock Option (right to buy)

INSIDER POWER
81.14
Last 97 transactions
Buy: 4 919 517 \| Sell: 1 365 507

Volume Correlation

Long: 0.44 (neutral)

Short: 0.53 (weak)

Signal:(63.878) Neutral

Verve Therapeutics, Inc. Correlation

10 Most Positive Correlations
POAI	0.905
EZGO	0.896
LPRO	0.893
HUGE	0.892
HELE	0.889
RKDA	0.889
ISSC	0.888
QH	0.888
INVE	0.886
ATRC	0.885

10 Most Negative Correlations
SOHU	-0.914
CENX	-0.914
LWAY	-0.908
CURI	-0.904
VFF	-0.903
LABP	-0.902
NN	-0.893
QRHC	-0.879
SMTC	-0.875
GRIN	-0.873

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Verve Therapeutics, Inc. Correlation - Currency/Commodity

-0.07
( neutral )

-0.11
( neutral )

0.00
( neutral )

-0.23
( neutral )

-0.10
( neutral )

-0.40
( neutral )

Verve Therapeutics, Inc. Financials

Annual	2023
Revenue:	$11.76M
Gross Profit:	$6.30M (53.61 %)
EPS:	$-3.12

FY	2023
Revenue:	$11.76M
Gross Profit:	$6.30M (53.61 %)
EPS:	$-3.12

FY	2022
Revenue:	$1.94M
Gross Profit:	$-4.77M (-245.75 %)
EPS:	$-2.91

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-6.78

Financial Reports:

No articles found.

Verve Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.